Rapid Micro Biosystems will announce Q4 and full year 2025 financial results on March 12, 2026, with a webcast.
Quiver AI Summary
Rapid Micro Biosystems, Inc. announced that it will release its financial results for the fourth quarter and full year 2025 on March 12, 2026, before the market opens. The company's management will hold a webcast conference call at 8:30 a.m. ET that same day, and the event will be accessible on its website. Rapid Micro Biosystems specializes in life sciences technology, providing automation solutions that enhance the manufacturing and release of healthcare products. Their flagship product, the Growth Direct system, modernizes microbial quality control testing in pharmaceutical manufacturing, improving efficiency, accuracy, and compliance. The company is based in Lexington, Massachusetts, with additional operations in Lowell, Switzerland, Germany, and the Netherlands.
Potential Positives
- Company will release fourth quarter and full year 2025 financial results, indicating positive transparency and engagement with investors.
- Management will host a webcast conference call, providing an opportunity for stakeholders to gain insight directly from the company's leadership.
- The Growth Direct system represents innovation in automation for microbial quality control, positioning the company as a leader in improving pharmaceutical manufacturing processes.
Potential Negatives
- The announcement of the financial results scheduled for March 12, 2026, may indicate a delay or lack of timely communication regarding financial performance, which can negatively affect investor confidence.
- The reliance on a single product, the Growth Direct system, for the company’s positioning in the market may pose a risk if the product does not meet market expectations or faces competition.
- None
FAQ
When will Rapid Micro Biosystems release their financial results?
Rapid Micro Biosystems will release their financial results on Thursday, March 12, 2026, before the market opens.
What time is the webcast conference call scheduled?
The webcast conference call is scheduled for 8:30 a.m. ET on Thursday, March 12, 2026.
How can I access the financial results webcast?
The live audio webcast can be accessed through the Company's website or via the provided link in the announcement.
Where is Rapid Micro Biosystems headquartered?
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts.
What products does Rapid Micro Biosystems focus on?
The company provides automation solutions for healthcare products, including biologics, vaccines, and sterile injectables.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RPID Insider Trading Activity
$RPID insiders have traded $RPID stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $RPID stock by insiders over the last 6 months:
- CAPITAL PARTNERS II, LLC LONGITUDE has made 0 purchases and 5 sales selling 157,739 shares for an estimated $663,949.
- ROBERT G. JR. SPIGNESI (PRESIDENT AND CEO) has made 0 purchases and 2 sales selling 51,167 shares for an estimated $197,481.
- SEAN M WIRTJES (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 23,281 shares for an estimated $90,485.
- JOHN J. ADDINGTON WILSON (CHIEF OPERATING OFFICER) has made 0 purchases and 2 sales selling 10,013 shares for an estimated $38,634.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RPID Hedge Fund Activity
We have seen 26 institutional investors add shares of $RPID stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARKMAN HEALTHCARE PARTNERS LLC removed 558,978 shares (-61.2%) from their portfolio in Q4 2025, for an estimated $1,621,036
- BLACKROCK, INC. removed 327,205 shares (-67.6%) from their portfolio in Q4 2025, for an estimated $948,894
- SCHONFELD STRATEGIC ADVISORS LLC removed 294,146 shares (-45.5%) from their portfolio in Q4 2025, for an estimated $853,023
- CITADEL ADVISORS LLC added 126,539 shares (+inf%) to their portfolio in Q4 2025, for an estimated $366,963
- 683 CAPITAL MANAGEMENT, LLC added 120,773 shares (+inf%) to their portfolio in Q4 2025, for an estimated $350,241
- MILLENNIUM MANAGEMENT LLC added 116,502 shares (+inf%) to their portfolio in Q4 2025, for an estimated $337,855
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 113,848 shares (+195.0%) to their portfolio in Q4 2025, for an estimated $330,159
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2025 financial results prior to the market open on Thursday, March 12, 2026.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Thursday, March 12, 2026. The live audio webcast will be accessible on the Company’s website and can be accessed with this link . The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn .
.jpeg)
